Autolus Therapeutics plc Increase (Decrease) in Accounts Receivable
Autolus Therapeutics plc (AUTL) reported Increase (Decrease) in Accounts Receivable of $20.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-11
- Autolus Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $16.74M, a 35.12% increase year-over-year.
- Autolus Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $3.63M, a 74.66% decline year-over-year.
- Autolus Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$8.57M.
- Autolus Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $6.00M.
- Autolus Therapeutics plc increase (decrease) in accounts receivable for fiscal 2025 was $24.16M.
- Autolus Therapeutics plc increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $20.38M 10-Q · filed 2026-08-11 | $11.81M derived: sum of 3 quarters · filed 2026-08-11 | $17.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $3.63M 10-Q · filed 2026-05-14 | -$4.94M derived: sum of 2 quarters · filed 2026-05-14 | $1.06M derived: sum of 3 quarters · filed 2026-05-14 | $13.46M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$8.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$2.57M derived: sum of 2 quarters · filed 2026-03-27 | $9.82M derived: sum of 3 quarters · filed 2026-08-11 | $24.16M 10-K · filed 2026-03-27 |
| 2025-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $18.39M derived: sum of 2 quarters · filed 2026-08-11 | $32.73M 10-Q · filed 2025-11-12 | $32.73M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $12.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $26.73M 10-Q · filed 2026-08-11 | $26.73M derived: sum of 3 quarters · filed 2026-08-11 | $26.73M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $14.34M 10-Q · filed 2026-05-14 | $14.34M derived: sum of 2 quarters · filed 2026-05-14 | $14.34M derived: sum of 3 quarters · filed 2026-05-14 | $14.34M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | $0.00 derived: sum of 3 quarters · filed 2026-03-27 | $0.00 10-K · filed 2026-03-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |